OCALA, Fla., April 07, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of AIM’s drug Ampligen as an intranasal therapy, reporting no serious adverse events, and paving the way for escalation of the dose in Cohort 2. The trial is a critical step in the company’s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

Originally posted here:

AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh